Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological DiseasesPRNewsWire • 03/31/22
Biohaven Pharmaceutical Holding's (BHVN) CEO Vlad Coric on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/25/22
BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTSPRNewsWire • 02/25/22
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp BiosciencesPRNewsWire • 02/25/22
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers SquibbPRNewsWire • 02/25/22
Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Earnings Next Week?Zacks Investment Research • 02/18/22
BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022PRNewsWire • 02/16/22
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary EndpointsBenzinga • 02/14/22
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South KoreaPRNewsWire • 02/14/22
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia ReportsPRNewsWire • 02/03/22
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With GlioblastomaBusiness Wire • 01/18/22
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of PainPRNewsWire • 01/10/22
BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPYPRNewsWire • 01/06/22
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United StatesPRNewsWire • 01/05/22
BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINEPRNewsWire • 12/13/21